Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of TJ0113 capsules in early-onset Parkinson's disease
CTR20262909Phase 3Active
- Sponsor
- Tianji Jishi Biotechnology
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TJ0113 in Parkinson's disease (PD), sponsored by Tianji Jishi Biotechnology. Started Jul 2026; status: active.
02
Drugs
TJ0113
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20262909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262909.